MD PhD Petter Brandal is a specialist in clinical oncology working at Oslo University Hospital (OUH) in Norway. He dissertated for his PhD in cancer genetics in 2006 and completed the clinical oncology specialty in 2011. Since 2012, he has been head of the clinical neuro-oncology programme at Department of Oncology, OUH, and he was head of the pediatric radiotherapy programme in the same department from 2012 to 2016. Dr. Brandal leads the Norwegian working group defining national guidelines for brain tumor diagnostics and treatment, and he also lead the work establishing national logistical demands for the primary diagnostic work-up of Norwegian brain tumor patients. Furthermore, he is leader of the national Norwegian neuro-oncology interest group and is member of the European Association of Neuro-Oncology (EANO) guideline committee.
Dr Brandal heads several clinical interventional studies for brain tumor patients. One of these is the PRO-GLIO study, which was funded by grants from The Norwegian Cancer Society and South-Eastern Norway regional Health Authority. PRO-GLIO compares proton versus photon radiotherapy in favorable prognosis diffuse glioma patients. Other interventional studies include industry-sponsored, academic and studies inside the European Organisation for Research and Treatment of Cancer (EORTC) portfolio.